Stories
Mostafa Kamal talks evolution of PBM industry, latest developments, in Fierce Healthcare panel
Industry experts share new insights from PBM industry, including GLP-1 weight-loss drugs, biosimilars and rising pharmaceutical costs
January 30, 2024Prime Therapeutics CEO and President Mostafa Kamal recently joined industry experts in a panel discussion about the evolving landscape of pharmacy benefit managers (PBMs).
On Jan. 18, Kamal joined moderators from Fierce Healthcare and panelists Adam Kautzner (President, Express Scripts), John O’Brien (President and CEO, National Pharmaceutical Council), and Anthony Loiacono (CEO, Capital Rx) in a panel entitled “Pharmacy Benefit Managers: The Evolving Discussion.”
“If you reflect on the history of PBMs, this industry has had an amazing track record of redefining itself every half a decade to decade, essentially to meet the emerging and evolving needs,” Kamal says. “I can’t think of a more exciting time to be in this industry. I think the innovation we’re seeing around pharmaceutical products creates a lot of hope.”
Experts explored the issues, changes and challenges impacting the role and influence of PBMs, delving into hot topics such as GLP-1 weight-loss drugs, biosimilars, rising pharmaceutical costs and the future of the PBM industry.
“With the proliferation of technology—artificial intelligence and other tools that we see emerging around us—I think it’s a unique moment in time for us to be able to look at the macro trends, identify significant needs and bring in technology to help us solve and move forward in ways that go beyond what we’ve done historically,” Kamal says, “which is managing unit costs and managing utilization, and move PBMs more toward managing total experiences and affordability and outcomes for patients—total health outcomes.”
Register for free to see the full panel discussion, then click on “Sessions” then “Panel: Pharmacy Benefit Managers: The Evolving Discussion | Closing Remarks.”
Related news
Stories
May 15, 2024
Prime/MRx experts share clinical insights for migraine treatment
Drs. Tracey Garcia and Amy Pappas, board-certified neurologists, reviewed migraine risk factors and treatments in a recent webinar moderated by Dr. Marci Chodroff, vice president of medical affairs
Stories
May 14, 2024
Prime/MRx real-world GLP-1 persistence and adherence data published in Journal of Managed Care & Specialty Pharmacy
Among the key findings from the study — among 4,066 members, Prime/MRx found 1 in 3 stayed on their GLP-1 and 27% took their medication as intended
Stories
May 14, 2024
Prime/MRx releases its first corporate social responsibility report
New report, an evolution of previous DEI reports, aims to demonstrate transparency and accountability for company’s corporate social responsibility journey